Application of index for representing intestinal flora metabolism homeostasis in autism early diagnosis kit

Through the detection of the GABA/Glu ratio of the intestinal metabolic homeostasis index, the problem of lack of biomarkers in the existing autism diagnosis methods is solved, and efficient and objective screening of early diagnosis of autism is achieved, and new The biological research tool improves the accuracy and scientificity of diagnosis.

CN119064592APending Publication Date: 2024-12-03THE SEVENTH AFFILIATED HOSPITAL SUN YAT SEN UNIV SHENZHEN
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411167146.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing autism diagnosis methods mainly rely on behavioral and psychological evaluation, and lack of exact biomarkers at the level of molecular biology, resulting in limited diagnostic efficiency and accuracy, especially in early diagnosis, missing important intervention periods .

Method used

Indicators of intestinal microbiota metabolic homeostasis, especially the ratio of γ-aminobutyric acid (GABA) and glutamic acid (Glu) metabolic balance as markers for early diagnosis of autism, were used to detect fecal samples, and the ratio of metabolic balance was used. Least Squares Discriminant Analysis (PLS-DA) and subject operation curve (ROC) analysis to achieve rapid and objective diagnostic screening.

Benefits of technology

Effectively improve the accuracy and efficiency of early diagnosis of autism, provide a new biological perspective and tool, which can objectively screen children with mild ASD, avoid the subjectivity of clinical staff, and significantly improve the science of diagnosis. Sex and reliability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119064592A_ABST
    Figure CN119064592A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biochemical diagnosis. The invention provides application of an index for representing intestinal flora metabolism homeostasis in an infantile autism early diagnosis kit. The index is an index for metabolic balance of gamma-aminobutyric acid and glutamic acid. Metabolic destabilization between gamma-aminobutyric acid (GABA) and glutamic acid (Glu) in intestinal flora is an important feature of children with light autism at the age of 3-6. According to the invention, an index for representing metabolic balance of GABA and Glu, namely a GABA / Glu ratio, is taken as a diagnostic marker for early screening of autism. The diagnostic marker not only has important application in clinical diagnosis, but also provides a new view angle and tool for scientific research, and is used for exploring and understanding a biological basis of autism. Detection of GABA and Glu can be rapidly carried out in a laboratory, subjectivity of clinical workers can be effectively avoided through obtained results, and mild ASD children can be effectively and objectively screened.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biochemical diagnosis technology, and in particular to the application of an indicator characterizing the metabolic homeostasis of intestinal flora in an early diagnosis kit for autism. Background Art

[0002] Autism spectrum disorder (ASD), also known as autism or autism spectrum disorder, is a pervasive neurodevelopmental disorder that affects social interaction, communication skills, and behavioral patterns. The pathogenesis of autism is complex, involving genetic and environmental factors, and existing diagnostic methods have certain limitations. At present, the diagnosis of autism mainly relies on behavioral and psychological assessment scales, and lacks accurate biomarkers at the molecular biological level, resulting in limited diagnostic efficiency and accuracy.

[0003] In addition, only about 18% of ASD patients can be diagnosed before the age of 3, missing the critical period for early intervention, which may lead to more serious cognitive and social dysfunction. Therefore, the development of a reliable autism risk assessment method is of great significance for early diagnosis and treatment.

[0004] In recent years, the potential role of gut microbiota (GM) in the pathogenesis of autism has attracted attention. ASD patients often have intestinal dysfunction, and GM imbalance may aggravate autism symptoms. Studies have shown that by improving the GM of ASD patients, symptoms can be significantly alleviated. Therefore, in-depth research on the differences in GM metabolites between ASD patients and healthy people is of great significance for the discovery of new biomarkers and therapeutic targets. Summary of the invention

[0005] The purpose of the present invention is to provide an indicator for characterizing the metabolic homeostasis of intestinal flora for use in an early diagnosis kit for autism, providing a new perspective and tool for scientific research to explore and understand the biological basis of autism.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides an application of an indicator characterizing the metabolic homeostasis of intestinal flora in an autism diagnosis product, wherein the indicator is an indicator of the metabolic balance of gamma-aminobutyric acid (GABA) and glutamate (Glu).

[0008] Preferably, the indicator of the metabolic balance of γ-aminobutyric acid and glutamate is the ratio of γ-aminobutyric acid to glutamate.

[0009] Preferably, the γ-aminobutyric acid and glutamic acid are γ-aminobutyric acid and glutamic acid produced by intestinal microbial metabolism.

[0010] Preferably, the γ-aminobutyric acid and glutamic acid are collected from feces.

[0011] Preferably, the autism diagnostic product is an early autism screening kit.

[0012] The present invention provides an application of an indicator characterizing the metabolic homeostasis of intestinal flora in an early diagnosis kit for autism, wherein the indicator is an indicator of the metabolic balance of γ-aminobutyric acid and glutamate. Metabolic instability between γ-aminobutyric acid (GABA) and glutamate (Glu) in the intestinal flora is an important feature of mild autistic children aged 3 to 6 years old. The present invention uses the GABA / Glu ratio, an indicator characterizing the metabolic balance of GABA and Glu, as a diagnostic marker for early screening of autism. This diagnostic marker not only has important applications in clinical diagnosis, but also provides a new perspective and tool for scientific research to explore and understand the biological basis of autism. The detection of GABA and Glu can be carried out quickly in the laboratory, and the results obtained can effectively avoid the subjectivity of clinical staff, and can effectively and objectively screen children with mild ASD. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 The bar graph shows the changes in the levels of all metabolites in the GABA and Glu metabolic pathways. The results suggest that compared with control children, ASD children have significant changes in multiple intestinal flora metabolites in the GABA and Glu metabolic pathways.

[0014] Figure 2 The figure is a scatter plot showing the results of partial least squares analysis (PLS-DA) to evaluate the changes in the levels of all metabolites in the GABA and Glu metabolic pathways derived from the microbiota. The results suggest that the GABA and Glu metabolic pathways are disordered in ASD children compared with control children.

[0015] Figure 3 This is a receiver operating curve (ROC) analysis diagram, showing the diagnostic efficacy of the intestinal GABA / Glu ratio for ASD. The results showed that the area under the curve (AUC) reached 0.972, indicating that the GABA / Glu ratio has a strong diagnostic efficacy. DETAILED DESCRIPTION

[0016] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0017] Example 1 Determination of GABA and Glu Content in Fecal Samples

[0018] This example detects stool samples from healthy people and autistic patients, and then performs correlation analysis to determine the correlation between the level of intestinal microbial metabolite acetic acid in stool samples and the onset and severity of autism symptoms. The specific steps are as follows:

[0019] (1) Sample source

[0020] Autism group: from Shanxi Fangzhou Autism Rehabilitation Institute, age distribution 0-14 years old. Inclusion criteria: ① According to the latest international diagnostic criteria, namely the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM5), 56 patients were diagnosed with mild autism; ② Gender is not limited. Exclusion criteria: ① Suffering from other mental illnesses (such as schizophrenia) and other neurodevelopmental disorders; ② Suffering from genetic metabolic diseases; ③ Suffering from severe neurological diseases and history of major physical diseases such as craniocerebral injury; ④ History of gastrointestinal infection or antibiotic use in the past month.

[0021] Control group: from the Green Field British Kindergarten in Datong, Shanxi. Inclusion criteria: ① healthy, without neurodevelopmental disorders; ② age and gender matching with the patient group. Exclusion criteria are the same as the autism group. All parents of the enrolled children were informed of the study and signed the informed consent.

[0022] This study was approved by the Medical Ethics Committee of the Seventh Affiliated Hospital of Sun Yat-sen University, ethics number: 2018041901.

[0023] (2) Collection of stool samples

[0024] Healthy subjects and autistic patients excrete their feces in designated feces collection basins, then prepare disposable medical feces sampling tubes, wear gloves, and collect feces. Avoid contamination caused by negligence. Once contamination is found, re-sampling should be performed. After collection, quickly freeze and store in a -80℃ refrigerator for future use. The amount of fecal sample collected is 0.3 grams.

[0025] (3) Analysis of acetic acid content in fecal samples

[0026] a. Sample preparation

[0027] Weigh an appropriate amount of each portion, add 1% FA 200μL pre-cooled ultrapure water, perform MP homogenization, then add 1% FA 800μL methanol / acetonitrile (1:1, v / v), vortex mix, low-temperature ultrasound for 30min, incubate at -20℃ for 1h to precipitate protein, centrifuge at 14000rcf4℃ for 20min, take the supernatant, and vacuum dry. For mass spectrometry detection, add 1% FA 100μLACN / water (1:1, v / v) to re-dissolve, centrifuge at 14000rcf4℃ for 15min, take the supernatant for sampling and analysis. Take an appropriate amount of sample and mix equal amounts as QC samples. QC samples are prepared in parallel according to the above method.

[0028] (2) HILIC LC-MS / MS analysis

[0029] The samples were separated using HILIC and a set of MRM mode data was collected. The relative quantitative analysis of neurotransmitter substances in the samples was mainly performed to obtain the peak area. The specific LC-MS / MS conditions are shown in Table 1.

[0030] Table 1

[0031] Column MS WatersUPLCamide2.1*100mm,1.7um Q-trap5500

[0032] (3) Data analysis

[0033] Analyst software was used to extract the MRM raw data of neurotransmitters, obtain the peak area of ​​each metabolite, and calculate the content of γ-aminobutyric acid and glutamate.

[0034] Example 2 Correlation analysis between intestinal microbial metabolite content in fecal samples and autism

[0035] The contents of intestinal microbial metabolites in the stool samples of the autism group and the control group measured in Examples 1 and 2 were analyzed using PLS-DA (partial least squares discriminant analysis).

[0036] The results are as follows Figure 1 As shown in the figure, the PLS-DA analysis shows that there are significant differences in the composition of intestinal microbial metabolites between patients with autism spectrum disorder (ASD) and typically developing individuals (TD).

[0037] The two groups of samples (autism group and control group) were respectively divided into two circles, indicating that the overall expression patterns of metabolites in these two groups were different. Therefore, the concentration of microbial intestinal metabolites can significantly distinguish healthy subjects from autism patients (explained variation 15%).

[0038] like Figure 2 As shown in the figure, the variable importance projection (VIP) scores of each metabolite ratio after metabolomics analysis are used to evaluate the importance of these ratios in distinguishing differences between sample groups. The VIP score is used as the horizontal axis and the metabolite ratio is used as the vertical axis. The size of the points in the figure reflects the fold change (Fold Difference) of each ratio, and the color depth of the points represents the P value after hypothesis test correction (-Log10 FDR), so as to comprehensively consider the influence and statistical significance of each metabolite ratio. We found that the GABA / Glu ratio is the most effective indicator to distinguish the two groups.

[0039] VIP is the variable importance for the Projection (VIP) in PLS-DA analysis. VIP is the variable weight value of the PLS-DA model variable, which can be used to measure the influence and explanatory power of the difference in the accumulation of each metabolite on the classification and discrimination of each group of samples. VIP≥1 is a common screening standard for differential metabolites. Among them, GABA / Glu in fecal samples is the main contributor to the discrimination of autism (VIP>1).

[0040] Example 3 Analysis of the accuracy of intestinal microbial metabolite levels in fecal samples in diagnosing autism

[0041] like Figure 3 As shown in the figure, the performance evaluation of the GABA / Glu ratio as a diagnostic model for autism is shown by the ROC curve. The red curve represents the performance of the validation cohort, with an AUC value of 0.972, showing a high diagnostic accuracy. The blue curve represents the performance of the screening cohort, with an AUC value of 0.814, which also reflects good diagnostic ability. These results show that the GABA / Glu ratio is an effective marker for the diagnosis of autism.

[0042] After using GABA / Glu as a diagnostic model for ROC curve analysis (receiver operating characteristic curve analysis) of all autism cases, the AUC values ​​(area under the ROC curve) were 0.814 (screening group) and 0.972 (validation group). AUC is defined as the area under the ROC curve for the classifier that plots the false positive rate (specificity) relative to the true positive rate (sensitivity). AUC is a measure of the accuracy with which a classifier can distinguish between two diagnostic groups (the closer to 1, the better the accuracy). This shows that the diagnosis of autism by the level of intestinal microbial metabolites in fecal samples has a high accuracy.

[0043] in conclusion

[0044] Following the detailed steps outlined above, stool samples will be collected from children participating in diagnostic screening. After sophisticated content analysis tests, these samples will be used to determine whether the child has autism or confirm that he or she is a member of the healthy population. This process not only enhances our ability to diagnose autism, providing an effective qualitative and quantitative method, but also provides us with important information to better understand this condition.

[0045] As can be seen from the above embodiments, the present invention provides an application of an indicator characterizing the metabolic homeostasis of intestinal flora in an early diagnosis kit for autism, wherein the indicator is an indicator of the metabolic balance of γ-aminobutyric acid and glutamate. Metabolic instability between γ-aminobutyric acid (GABA) and glutamate (Glu) in the intestinal flora is an important feature of mild autistic children aged 3 to 6 years. The present invention uses the GABA / Glu ratio, an indicator characterizing the metabolic balance of GABA and Glu, as a diagnostic marker for early screening of autism. This diagnostic marker not only has important applications in clinical diagnosis, but also provides a new perspective and tool for scientific research to explore and understand the biological basis of autism. The detection of GABA and Glu can be carried out quickly in the laboratory, and the results obtained can effectively avoid the subjectivity of clinical staff, and can effectively and objectively screen children with mild ASD.

[0046] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of an indicator for characterizing the metabolic homeostasis of intestinal flora in autism diagnosis products, It is characterized in that The index is an index of the metabolic balance of gamma-aminobutyric acid and glutamate.

2. The use according to claim 1, It is characterized in that The index of the metabolic balance of γ-aminobutyric acid and glutamate is the ratio of γ-aminobutyric acid to glutamate.

3. The use according to claim 2, It is characterized in that The γ-aminobutyric acid and glutamic acid are γ-aminobutyric acid and glutamic acid produced by intestinal microbial metabolism.

4. The use according to any one of claim 3, It is characterized in that The γ-aminobutyric acid and glutamic acid are collected from feces.

5. The use according to any one of claims 1 to 4, It is characterized in that The autism diagnostic product is an early autism screening reagent kit.

Citation Information

Cited By

  • Application of intestinal probiotics and metabolites thereof in treating autism spectrum disorder

    CN121360141A